Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06251024 | Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older | PHASE2 | COMPLETED | 4,541 | — | — | Apr 2, 2024 | Mar 11, 2025 | Mar 10, 2026 | 25 | Australia, Chile +4 |
Number of participants experiencing RSV-LRTD (RSV A and/or RSV B) ≥ 14 days after vaccination
| Arm | Type | Description |
|---|---|---|
| Group 1: RSV vaccine candidate | EXPERIMENTAL | Participants will be enrolled in a 1:1 ratio to receive a single IM administration of the RSV vaccine candidate. |
| Group 2: placebo | PLACEBO_COMPARATOR | Participants will be enrolled in a 1:1 ratio to receive a single IM administration of the placebo. |
| Name | Type | Description |
|---|---|---|
| RSV vaccine candidate | BIOLOGICAL | Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection |
| Placebo | BIOLOGICAL | Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection |
Inclusion Criteria: * Aged 60 years or older on the day of inclusion * A female participant is eligible to participate if she is not pregnant or breastfeeding and: • Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be postmenopausal for at least 1 y...